First humans dosed in early trial for rare liver disease
NCT ID NCT06798454
Summary
This was the first study in humans for an experimental drug called PVT201. The main goal was to check its initial safety and see how the body processes it. Researchers gave single, increasing doses to 24 healthy volunteers and a small group of patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC). They closely monitored everyone for side effects and measured drug levels in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research
Adelaide, South Australia, 5000, Australia
Conditions
Explore the condition pages connected to this study.